Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2003-11-25
2010-12-07
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C424S204100, C435S235100, C435S236000, C435S239000
Reexamination Certificate
active
07846455
ABSTRACT:
Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5840520 (1998-11-01), Clarke et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 5882651 (1999-03-01), Murphy et al.
patent: 5932222 (1999-08-01), Randolph et al.
patent: 6264957 (2001-07-01), Collins
patent: 6689367 (2004-02-01), Collins et al.
patent: 6699476 (2004-03-01), Collins et al.
patent: 6713066 (2004-03-01), Collins et al.
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO-93/21310 (1993-10-01), None
patent: WO-97/06270 (1997-02-01), None
patent: WO-97/12032 (1997-04-01), None
patent: WO-97/20468 (1997-06-01), None
patent: WO-98/02530 (1998-01-01), None
patent: WO-98/43668 (1998-10-01), None
patent: WO-99/15631 (1999-04-01), None
Collins et al., “Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role for the Transcription Elongation Factor from the 5' Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development,” PNAS, vol. 92, pp. 11563-11567 (Dec. 1995).
Firestone et al., “Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts)cpts-248/404 Live Attenuated Virus Vaccine Candidate,” Virology, vol. 225 No. 2, pp. 419-422 (Nov. 1996).
Whitehead et al., “Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) cpts530/1030 to RSV Vaccine Candidate cpts248/404 Increases Its Attenuation and Temperature Sensitivity,” Journal of Virology, vol. 73 No. 2, pp. 871-877 (Feb. 1999).
Baron et al., “Rescue of Rinderpest Virus from Cloned cDNA,” J. Virol. 71:1265-1271, 1997.
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter,” J. Virol. 73:251-259, 1999.
Bukreyev, et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene,” J. Virol. 70:6634-41, 1996.
Bukreyev, et al., “Interferon Υ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity,” Proc. Nat. Acad. Sci. USA 96:2367-2372, 1999.
Collins et al., “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene,” Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991.
Collins et al., “Rescue of a 7502-Nucleotide (49.3% of Full Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA,” Virology 195:252-256, 1993.
Connors et al., “A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes,” Virology 208:478-484, 1995.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,” J. Virol, 68:713-719, 1994.
Conzelmann, “Genetic Manipulation of Non-Segmented Negative-strand RNA Viruses,” J. Gen. Virol. 77:381-389, 1996.
Crowe, et al., “A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type challenge in Seronegative Chimpanzees,” Vaccine 12:893-790, 1994.
Crowe, et al., “Acquisition of thetsPhenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene,” Virus Genes 13:269-273, 1996.
Dimock, et al., “Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3,” J. Virol, 67:2772-2778, 1993.
Durbin, et al., “Minimum Protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus type 3 and Evaluation of the Rule of Six,” Virology 234:74-83, 1997.
Durbin et al., “Recovery of Infectious Human Parainfluenza virus type 3 from cDNA,” Virology 235:323-332, 1997.
Grosfeld et al., “RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Required RSV Superinfection for Efficient Synthesis of Full-Length MRNA,” J. Viorol. 69: 5677-5686, 1995.
He et al., “Recovery of Infectious SV5 from Cloned DNA and Expression of a foreign Gene,” Virology 237:249-260, 1997.
Hoffman et al., “An Infectious Clone of Human Parainfluenza virus Type 3,” J. Virol. 71:4272- 4277, 1997.
Jin et al., “Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV,” Virology 251:206-214, 1998.
Juhasz et al., “The Temperature-Sensitive (ts) Phenotype of a Cold-Passaged (cp) Live Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designatedcpts530, Results from a Single Amino Acid Substitution in the L Protein,” J. Virol. 71:5814-5819, 1997.
Kato et al., “Initiation of Sendai Virus Multiplication From Transfected cDNA or RNA with Negative or Positive Sense,” Genes to Cells 1:569-579, 1996.
Kuo at al., “Effect of Mutations in the Gene-Start and Gene-End Sequence Motifs on Transcription of Monocistronic and Dicistronic Minigenomes of Respiratory Syncytial Virus,” J. Virol. 70:6892-6901, 1996.
Lawson et al., “Recombinant Vesicular Stomatitis Viruses from DNA,” Proc. Natl. Acad. Sci. USA 92:4477-4481, 1995.
McIntosh et al., “Respiratory syncytial Virus,” in virology, pp. 1046 and 1047, Fields et al., eds., 2nd ed., Raven Press, Ltd, New York, 1990.
Mink, et al., “Nucleotide Sequences of the e' Leader and 5' Trailer Regions of Human Respiratory Syncytial Virus Genomic RNA,” Virology 185:615-624, 1991.
Murphy et al., “Current Approaches to the Development of Vaccines Effective Against Parainfluenza and Respiratory Syncytial Viruses,” Virus Res. 11:1-15, 1988.
Palese et al., “Negative-Strand RNA Viruses: Genetic Engineering and Applications,” Proc. Natl. Acad. Sci. USA 93:11354-11358, 1996.
Pastey et al., “Structure and Sequence Comparison of Bovine Respiratory Syncytial Virus Fusion Protein,” Virus. Res. 29:195-202, 1993.
Pastey et al., “Nucleotide Sequence Analysis of the Non-Structural NS1(1C) and NS2 (1B) Protein Genes of Bovine Respiratory Syncytial V
Collins Peter L.
Murphy Brian R.
Whitehead Stephen S.
Lucas Zachariah
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Attenuated chimeric respiratory syncytial virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated chimeric respiratory syncytial virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated chimeric respiratory syncytial virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159226